» Articles » PMID: 34122066

Management of Ineffective Esophageal Hypomotility

Overview
Journal Front Pharmacol
Date 2021 Jun 14
PMID 34122066
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Esophageal hypomotility in general and especially ineffective esophageal motility according to the Chicago criteria of primary motility disorders of the esophagus, is one of the most frequently diagnosed motility disorders on high resolution manometry and results in a large number of patients visiting gastroenterologists. Most patients with esophageal hypomotility present with gastroesophageal reflux symptoms or dysphagia. The clinical relevance of the motility pattern, however, is not well established but seems to be correlated with disease severity in reflux patients. The correlation with dysphagia is less clear. Prokinetic agents are commonly prescribed as first line pharmacologic intervention to target esophageal smooth muscle contractility and improve esophageal motor functions. However, the beneficial effects of these medications are limited and only confined to some specific drugs. Serotonergic agents, including buspirone, mosapride and prucalopride have been shown to improve parameters of esophageal motility although the effect on symptoms is less clear. Understanding on the complex correlation between esophageal hypomotility and esophageal symptoms as well as the limited evidence of prokinetic agents is necessary for physicians to appropriately manage patients with Ineffective Esophageal Motility (IEM).

Citing Articles

Esophageal Disorders in the Older Adult.

Babbar S, Sachar M, Faye A, Knotts R Curr Treat Options Gastroenterol. 2025; 23(1).

PMID: 40061442 PMC: 11887613. DOI: 10.1007/s11938-025-00468-6.


Effect of Anti-reflux Mucosal Ablation on Esophageal Motility in Patients With Gastroesophageal Reflux Disease: A Study Based on High-resolution Impedance Manometry.

Chen C, Chou C, Yuan M, Tsai K, Wu J, Liao W J Neurogastroenterol Motil. 2025; 31(1):75-85.

PMID: 39779206 PMC: 11735199. DOI: 10.5056/jnm24055.


A practical approach to ineffective esophageal motility.

Kamboj A, Katzka D, Vela M, Yadlapati R, Ravi K Neurogastroenterol Motil. 2024; 36(9):e14839.

PMID: 38837280 PMC: 11321916. DOI: 10.1111/nmo.14839.


The Saudi Gastroenterology Association consensus on the clinical care pathway for the diagnosis and treatment of GERD.

Alzahrani M, Alqaraawi A, Alzubide S, Abufarhaneh E, Alkhowaiter S, Alsulaimi M Saudi J Gastroenterol. 2024; 30(6):353-368.

PMID: 38813746 PMC: 11630483. DOI: 10.4103/sjg.sjg_82_24.


Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies.

El Baassiri M, Raouf Z, Badin S, Escobosa A, Sodhi C, Nasr I J Neuroinflammation. 2024; 21(1):124.

PMID: 38730498 PMC: 11083845. DOI: 10.1186/s12974-024-03118-3.


References
1.
Koshino K, Adachi K, Furuta K, Ohara S, Morita T, Nakata S . Effects of mosapride on esophageal functions and gastroesophageal reflux. J Gastroenterol Hepatol. 2010; 25(6):1066-71. DOI: 10.1111/j.1440-1746.2010.06280.x. View

2.
Ramirez B, Richter J . Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993; 7(1):5-20. DOI: 10.1111/j.1365-2036.1993.tb00064.x. View

3.
Leelakanok N, Holcombe A, Schweizer M . Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis. Clin Drug Investig. 2015; 36(2):97-107. DOI: 10.1007/s40261-015-0360-0. View

4.
Sweis R, Heinrich H, Fox M . Variation in esophageal physiology testing in clinical practice: Results from an international survey. Neurogastroenterol Motil. 2017; 30(3). DOI: 10.1111/nmo.13215. View

5.
Lei W, Hung J, Liu T, Yi C, Chen C . Influence of prucalopride on esophageal secondary peristalsis in reflux patients with ineffective motility. J Gastroenterol Hepatol. 2017; 33(3):650-655. DOI: 10.1111/jgh.13986. View